CANNABIS
Dronabinol improves chronic non-cancer pain when added to standard opioid therapy
J Pain. 2008 Mar;9(3):254-6430 chronic pain patients who were on stable doses of opioids received a single dose of each of10 mg of dronabinol (a synthetic cannabinoid), 20 mg dronabinol, or placebo in a random order, followed by 4 weeks of 5-60 mg dronabinol (open-label). The primary outcome was total pain relief at 8 hours in the randomized phase and change in pain intensity on a numeric rating scale (NRS) in the open-label phase. Secondary outcomes included patient satisfaction, side effects, dropouts, pain bothersomeness, mood, evoked pain, and plasma levels of THC. Dronabinol reduced pain intensity and improved satisfaction among patients with chronic non-cancer pain when added to standard opioid therapy.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
